The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome

被引:0
作者
Ponder, BAJ [1 ]
机构
[1] Univ Cambridge, Cambridge Inst Med Res, Addenbrookes Hosp, Cambridge CB2 2XY, England
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Different specific mutations in the ret tyrosine kinase give rise to different clinical types of the inherited cancer syndrome multiple endocrine neoplasia type 2 (MEN 2), The explanation for these genotype-phenotype correlations is not yet certain. Several lines of evidence suggest that they result either from different levels of RET activation induced by different mutations or, in one class of mutation, possibly from altered substrate specificity of the RET tyrosine kinase, ret is expressed during development in a lineage of neuroectodermal cells that gives rise to the thyroid C cells and the adrenal medulla, which are involved in tumor formation in MEN 2, ret is also expressed in the enteric autonomic nervous system. Inactivating mutations of ret lead to Hirschsprung's disease, a congenital absence or maldevelopment of the enteric plexuses, whereas activating mutations in one variety of the MEN 2 syndrome lead to their overgrowth. The range of phenotypic expression seen in families with different ret mutations and the variation within families with the same mutation provide a potentially interesting and tractable system for the analysis of both the relationship between phenotype and genotype and the effects of modifier genes.
引用
收藏
页码:1736S / 1741S
页数:6
相关论文
共 79 条
  • [1] MOLECULAR CONTROL OF CELL FATE IN THE NEURAL CREST - THE SYMPATHOADRENAL LINEAGE
    ANDERSON, DJ
    [J]. ANNUAL REVIEW OF NEUROSCIENCE, 1993, 16 : 129 - 158
  • [2] MUTATION ANALYSIS OF THE RET RECEPTOR TYROSINE KINASE IN HIRSCHSPRUNG DISEASE
    ANGRIST, M
    BOLK, S
    THIEL, B
    PUFFENBERGER, EG
    HOFSTRA, RM
    BUYS, CHCM
    CASS, DT
    CHAKRAVARTI, A
    [J]. HUMAN MOLECULAR GENETICS, 1995, 4 (05) : 821 - 830
  • [3] Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a hirschsprung disease patient
    Angrist, M
    Bolk, S
    Halushka, M
    Lapchak, PA
    Chakravarti, A
    [J]. NATURE GENETICS, 1996, 14 (03) : 341 - 344
  • [4] AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305
  • [5] THE RET PROTOONCOGENE IN SPORADIC PHEOCHROMOCYTOMAS - FREQUENT MEN 2-LIKE MUTATIONS AND NEW MOLECULAR DEFECTS
    BELDJORD, C
    DESCLAUXARRAMOND, F
    RAFFINSANSON, M
    CORVOL, JC
    DEKEYZER, Y
    LUTON, JP
    PLOUIN, PF
    BERTAGNA, X
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (07) : 2063 - 2068
  • [6] A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A
    Berndt, I
    Reuter, M
    Saller, B
    Frank-Raue, K
    Groth, P
    Grussendorf, M
    Raue, F
    Ritter, MM
    Höppner, W
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (03) : 770 - 774
  • [7] BOLINO A, 1995, ONCOGENE, V10, P2415
  • [8] Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation
    Bongarzone, I
    Vigano, E
    Alberti, L
    Borrello, MG
    Pasini, B
    Greco, A
    Mondellini, P
    Smith, DP
    Ponder, BAJ
    Romeo, G
    Pierotti, MA
    [J]. ONCOGENE, 1998, 16 (18) : 2295 - 2301
  • [9] Borrello MG, 1995, ONCOGENE, V11, P2419
  • [10] Neurturin responsiveness requires a GPI-linked receptor and the Ret receptor tyrosine kinase
    BujBello, A
    Adu, J
    Pinon, LGP
    Horton, A
    Thompson, J
    Rosenthal, A
    Chinchetru, M
    Buchman, VL
    Davies, AM
    [J]. NATURE, 1997, 387 (6634) : 721 - 724